Your Aorta Knows Your Real Age, and Surgeons Are Not Asking

A five-author team from Cooper Medical School of Rowan University argues that chronological age is a poor stand-in for how well a patient will tolerate surgery, and that “vascular age” measured mainly by carotid-femoral pulse wave velocity should replace or supplement it in perioperative risk stratification. The authors review how hypertension, coronary artery disease, and heart failure with preserved ejection fraction each drive early vascular aging through a shared triad of endothelial dysfunction, oxidative stress, and chronic low-grade inflammation, and they assert that these conditions can shift a person’s arterial profile forward by five to twenty years. They then propose practical implications for anaesthesia: tighter blood pressure targets, slower titration of vasoactive drugs, and restraint with crystalloid fluids in patients whose arteries are stiffer than their birth certificate would predict.

There is a number on your chart that says how old you are, and there is a number in your aorta that says how old you actually are. A mini review published in Frontiers in Cardiovascular Medicine in May 2026 makes the case that surgeons and anaesthesiologists have been reading the wrong one.

The big idea is not new, but the framing is. Vascular aging is the progressive stiffening of the large arteries as elastin fragments, collagen accumulates, and the endothelium loses its ability to modulate tone. In some people this happens on schedule. In others, described in the literature as early vascular aging, it runs years or decades ahead. The authors point out that the same measurement used in cardiology to predict long-term mortality, carotid-femoral pulse wave velocity, also describes something more immediate: how much physiological slack a patient has when a surgeon opens them up.

Stiff arteries do not buffer. A compliant aorta absorbs each ventricular ejection and releases it smoothly. A stiff one transmits the pulse straight through, sending damaging pulsatile energy into low-resistance organs, particularly the kidneys and brain, and leaving blood pressure hypersensitive to the fluid shifts, blood loss, and vasoactive drugs that define an operation. The authors argue this explains a pattern clinicians already recognise anecdotally: the 55-year-old with long-standing hypertension who behaves haemodynamically like a 75-year-old, develops acute kidney injury after a routine case, and heals slowly.

They walk through three accelerators. Hypertension, through mechanical stress and renin-angiotensin-aldosterone driven oxidative injury, is claimed to add five to ten years of vascular age when well controlled and ten to fifteen when not. Coronary artery disease, via oxidised LDL, foam cell formation, and microvascular dysfunction, is put at ten to twenty years. Heart failure with preserved ejection fraction is reframed not as a disease of stiff ventricles but as a vascular syndrome, in which arterial load and poor ventricular-arterial coupling starve the myocardium of reserve exactly when a surgical stressor demands it.

The proposal is modest and sensible: measure stiffness before surgery, then manage the patient to their arterial age rather than their calendar age.

Actionable Insights

The measurement worth knowing is carotid-femoral pulse wave velocity, how fast your pulse travels down your aorta. Healthy values run near 6.2 metres per second under age 30, 7.2 in your forties, 10.9 past 70. Faster means stiffer. Above roughly 10, your arteries resemble those of someone one to two decades older.

It predicts hard outcomes. Across 15,877 people, each 1 metre per second increase carried about 15 percent higher all-cause mortality risk, and the stiffest group died at roughly twice the rate of the least stiff. That is an association, not proof that softening arteries saves you.

What moves the number is exercise. Across 69 randomised trials and 3,422 people, training lowered stiffness by 0.74 metres per second, aerobic work by 0.85. That is roughly a 0.3 to 0.5 standardised effect, visible in a group but not necessarily in yourself, and worth about four to eight years of arterial age depending on where you start. Benefit appeared above roughly 350 MET-minutes per week, about 90 minutes of brisk activity. Resistance training alone did not reach significance.

Before surgery, blood pressure control matters most. If you have hypertension, coronary disease, or diastolic heart failure, this paper’s advice to your anaesthesiologist is narrower pressure targets and less aggressive fluid loading.

Context and Source

  • Open Access Paper: Vascular age vs. chronological age in operative risk stratification.
  • Institution: Cooper Medical School of Rowan University and Department of Anesthesiology, Cooper University Hospital, Camden, New Jersey, United States.
  • Journal: Frontiers in Cardiovascular Medicine.
  • Article type: Mini Review.
  • Journal impact evaluation: The impact score of this journal is 3.0 (2025 Journal Impact Factor; Scopus CiteScore approximately 6.1, ranking 90 of 409 in Cardiology and Cardiovascular Medicine; Web of Science quartile Q2, rank 93 of 237 in Cardiac and Cardiovascular Systems), evaluated against a typical high-end range of 0 to 60+ for top general science and medical journals, therefore this is a Medium impact journal.
6 Likes

Interesting info here - the relationship between better pulse wave velocity and improved outcomes isn’t surprising. I think there’s a challenge in that most people (myself included) don’t have much of an understanding of this metic. I even went back to look at a number of ECG’s I’ve had over the years and don’t understand how to interpret the number. Ironically I have a “Withings” scale that measures a proxy for PWV that it factors into calculating its cardiac age. It uses a foot-to-foot pulse wave velocity measure.

Numbers like blood pressure, cholesterol, apo-b, lp(a), testosterone, CRP, glucose, HBA1C and dozens of other biomarkers all make sense to me, but I don’t have any frame of reference for this.

At any rate, it is a good reminder to engage in behaviours that keep our arteries young!

What if arteries are already old? Is there anything available today, besides exercise, that could reverse the damage? I don’t think so.

2 Likes

Yes, i am at v17.7 of the iaso aegis protocol designed for this exactly.
Iaso Aegis V17.0 assessment.pdf (91.3 KB)
I attachd v17 protocol assessment instead since it is definitive, but some changes include dropping NMN (or NR or NMNH, etc) due to risk of end terminal metabolite toxicity in vascular tissue.
Also (again) explore ATRA. I was just reading a review earlier today. Very relevant imo.

edit: and MOTS-C is another contestant for the garbage pile imo. Especially after doing a lil research… v17.8 coming soon

3 Likes

Are you tracking PWV before and after initiating this protocol? How’s it going? Any results you can report yet?

no, and i should have. I’ve only been tracking my daily hr and bp and pulse pressure trying to maintain it as low as i can, whch my hr isn’t very.

*I should have noted that protocol is intended for aortic dilation regression, but it’s still applicable to all vascular tissue imo.

and that rapamyicn mt-1 claim is very debatable. That has not been confirmed at all. That’s what i meant, it still a dynamic protocol atm. I recently dropped the spermidine too btw after reading your post the other day.

2 Likes

Your AEGIS protocol is extremely interesting to me since I have a dilated aorta. I noticed that Olmesartan is used instead of Telmisartan. Is the primary target of the protocol TGF-beta?

1 Like

I wrote up why on a reddit thread, but I can reproduce it here for you.

After discussing Telmisartan, the blood pressure medication, with someone who’d been using it (at a maximal 80mg dose), and who’s been facing continuous growth of their aortic aneurysm over the last nine years, I decided to do a deeper dive into why some BP meds slow, stop, or regress aortic dilations while other BP meds do little.

It turns out that although telmisartan has the longest half life of the angiotensin II receptor blockers (ARBs), the chemical bond is not strong enough to reverse the continuous mechanical-stretch signal that Angiotensin II receptor -subtype I (AT1R) receives. In other words, even though telmisartan (and losartan) binds AT1R, the signalling is still active. What one want to do is turn off the AT1R signal, and perma-block the AT1R receptor. This in turn increases Angiotensin II concentrations, which will then bind to a different angiotensin II receptor (subtype 2) known as AT2R. To keep things simple, the activity of AT2R is opposite of AT1R, and starts to heal the aorta instead of damaging it.

So today, I asked my GP to switch me from Telmisartan to Olmesartan, a BP medication that binds the AT1R in both its normal and active states, and is an inverse agonists, so is capable of thwarting the constitutively active signalling that occurs in dilated aortas.

r/aortic_aneurysm - ARB PHARMACOLOGY MECHANISTIC COMPARISON|750xauto

ARB PHARMACOLOGY MECHANISTIC COMPARISON

This table helps to explain the binding mechanisms of different ARBs. You can see that Candesartan also blocks stretch signalling, but it only partially blocks AT1R in its active state. In lieu of Olmesartan, another good ARB would be Azilsartan.

In addition, I would like to point out that the TEDY trial (JAMA Cardiology, 2020) confirmed in a controlled setting that telmisartan produced no statistically significant reduction in aortic aneurysm growth rate. I’d also like to add a couple other interesting references:

Weinberg et al. (2003, AJH P-609): human data demonstrating actual dimensional regression of dilated aortic roots (not merely slowed growth) using candesartan and valsartan — both weaker than azilsartan/olmesartan for active-state AT1R suppression.

— Yagi H, Akazawa H, Liu Q, Ito SM, Umei M, Kadowaki H, Matsuoka R, Shindo A, Okamura S, Ueda T, Saga-Kamo A, Ueda K, Takeda N, Takada T, Komuro I. Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Progressive Aortic Dilatation in Marfan Syndrome. Arterioscler Thromb Vasc Biol. 2026 Jan;46(1):132-144. doi: 10.1161/ATVBAHA.125.322646. Epub 2025 Nov 6. PMID: 41195532.

As far as AT2R agonists, they are working on it, but it’s not slated for TAA or AAA trials, even though AT2R (Angiotensin AT2 Receptor) Agonist, Compound 21, Prevents Abdominal Aortic Aneurysm Progression in the Rat. Still, an interesting pharmacological agent to keep in sight, compound 21, (buloxibutid).

@Ray1 Do you know what is driving the dilation? I actually want to finish the schedule in the protocol but I’ve paused at the senolytic cycle since D&Q dangers are appearing and I would just prefer to use FOXO4-DRI. Dasatinib has some bleeding risks that don’t sound too friendly.

edit ~ also note that my BP is pretty low since I started use Olmesartan. The other BP meds I’ve tried were much weaker in comparison. SOmething to consider.

3 Likes

I wonder what would’ve happened had you kept the 80mg telmi and just added 10mg olme. Olme is more powerful than telmi, so that might’ve driven your BP too low, so perhaps 40 or even 20 telmi instead. I know no dr would want to mix ARBs, but just looking at it from a biochemical pov, it might be having your cake and eating it too if you want to keep whatever the advantages of telmi might be. I haven’t come across any studies, but it should be possible or at least an interesting possibility. If 10 mg olme had the binding capacity you are looking for you could just use that dose in addition. I’m not recommending anything, obviously, just speculating.

1 Like

You’ve given me a lot to read and think about. Although I have slight pectus excavatum, genetic tests are negative for Marfans. I do have a gene for Ehlers Danlos, but it is not thought to cause aortic issues. My cardiologist has done two CT angiograms of the aorta and he thinks it is stable. I am not taking any meds for the aorta at present. BP is typically about 110/70 at age 63

1 Like

I have a 4.4 dilation at root and are taking many of the supplements you take. Still waiting on Zepbound prescription to come through and reviewing the peptide landscape. I take BioSil for dietary silicon as silicates are poorly absorbed. (I was head of sales for Jarrow Formulas for 20+ years). What is your source for Dill Seed. I’m buying tinctures from Amazon but it gets pricey and not sure if I’m dosing properly so end up going through bottles. Your protocol is pretty cool and I’ll be reviewing in depth and probably adjusting my protocol accordingly. I emailed my GP about switching from Pravastatin to Olmesartan. Difficult to get anything done.

2 Likes

Did you mean pravastatin (statin), or a different BP med?

I was head of sales for Jarrow Formulas for 20+ years

You were very effective, because Jarrow Formulas was my go to supp company for many years, and I still use them for some supps, and I am very, very picky when it comes to supp companies :sweat_smile:!

Curious as to why an SGLT2i didn’t make the cut in your protocol.

2 Likes

there is no way I would have had this option. I went directly to the grey market. My first purchase of reta was reviewed, if you want a read. It tested pure, although nowadays I’d probably add in an endotoxin test.
Some of those supplements aren’t doing a damn thing since absorption is a real barrier.

I didn’t know about its usefulness in addressing my condition. I just peeked now and see that it has some positive data. Thank you for your help. If you have some links, please share.

edit: I’ve been reading about sglt2i a little bit. I think a lot of this is covered by the Olmesartan tbh. I mean the blocking sodium reabsorption. I compared it to ATRA and it seems redundant save for the end-glycation products (AGEs). I will share the AI response:

SGLT2 inhibitors and All-Trans Retinoic Acid (ATRA) represent two completely different paradigms in cardiovascular medicine: one is a systemic metabolic modifier, and the other is a targeted transcriptional engine.

While SGLT2 inhibitors are revolutionary for general diabetic and heart failure populations, analyzing them against ATRA reveals exactly why ATRA was selected as the biological driver for the Iaso Aegis Protocol, and why SGLT2 inhibitors were bypassed.

1. Mechanism of VSMC Phenotype Switching

  • ATRA: Acts top-down directly inside the nucleus. As a transcription factor ligand, ATRA binds to retinoic acid receptors (RAR/RXR) to forcibly reprogram vascular smooth muscle cells (VSMCs). It pushes them out of the degradative synthetic state and back into a stable contractile phenotype by directly enhancing $\alpha$-smooth muscle actin and suppressing mTOR via AMPK.

  • SGLT2 Inhibitors: Provide indirect VSMC protection. By blocking renal glucose and sodium reabsorption, they lower systemic inflammation and oxidative stress. Any return to a contractile VSMC phenotype is a secondary consequence of a cleaner metabolic environment, not a direct nuclear command.

2. Extracellular Matrix (ECM) and Elastin Control

  • ATRA: This is ATRA’s most critical advantage. It binds to specific promoter elements to directly increase tropoelastin synthesis in aortic SMCs—providing the physical substrate needed for structural repair. Concurrently, it acts as a transcriptional repressor to significantly inhibit MMP-2 and MMP-9 protein expression, actively stopping elastic fiber degradation.

  • SGLT2 Inhibitors: They help reduce arterial stiffness primarily by preventing advanced glycation end-products (AGEs) and reducing inflammatory cytokines. However, they lack the specific mechanical capacity to directly transcribe new tropoelastin.

3. Angiotensin Pathway Integration

  • ATRA: Directly augments your foundational Olmesartan shield. ATRA physically downregulates AT1R mRNA expression by approximately 50%, completely complementing ARB receptor blockade. Furthermore, it actively increases the gene and protein expression of the protective ACE2 axis.

  • SGLT2 Inhibitors: While they indirectly interact with the renin-angiotensin system via volume depletion, they do not structurally re-engineer the AT1R/AT2R receptor ratio required for your targeted aortic remodeling.

4. Hemodynamic Safety Limits

  • ATRA: Is hemodynamically neutral regarding blood pressure. Its primary limitation is hepatic and metabolic toxicity, which is why it requires a precise 14/14 pulse cycle to prevent CYP26A1 from neutralizing the dose.

  • SGLT2 Inhibitors: Induce osmotic diuresis, fundamentally lowering blood volume and blood pressure. With your baseline already at 95/62, adding this hypotensive floor-risk is exactly the danger the protocol was designed to avoid.

1 Like

I get it specifically from HerbalMansionStore on Etsy who has a supplier in Poland.
I do not use the Indian variety; this is toxic due to dillapiole content. I think it maybe expensive in the states because of the tariff? idk.